Please login to the form below

Not currently logged in
Email:
Password:

Amgen's John Kearney to lead ABPI's pricing negotiation team

Negotiators will also include GSK's Erik van Snippenberg and Pfizer's Jon Emms

The ABPI has unveiled the team of pharmaceutical executives that will represent the UK industry when pricing negotiations with the Department of Health formally begin.

The industry and DH will sit down next month to begin working out details of the UK's next pricing scheme, which will replace the current Prescription Pricing and Reimbursement Scheme (PPRS).

Heading up the ABPI's negotiating side will be team chair John Kearney, who is UK and Ireland general manager at biopharmaceutical company Amgen.

Serving with him will be GSK's UK general manager Erik van Snippenberg, Pfizer's UK managing director Jon Emms, UCB's British and Irish Isles managing director Matthew Speers and Alliance's executive director Pete Butterfield.

Keen to stress the inclusive nature of its team, the ABPI said it was representative of different sized companies as well as the different geographies within the UK industry.

The UK industry body will also provide a team of its own to support the pharma negotiators and this will be led by ABPI commercial director Alison Clough.

It is currently proposed that from 2014 a value-based pricing (VBP) system, incorporating a broader assessment of a product's worth, will be used to determine prices for medicines that are newly launched onto the UK market, while an updated version of the PPRS will be used to decide the price of branded drugs already available.

10th August 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Reynolds-MacKenzie

Reynolds-MacKenzie is the multi award-winning specialist public relations practice within OPEN Health; the first ever agency in the health communications...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....